--> Nigeria Health - Oxford Business Group

Licence or Product Purchase Required

You have reached the limit of premium articles you can view for free. 


Get expert, on-the-ground insights into the latest business and economic trends in more than 30 high-growth global markets. Produced by a dedicated team of in-country analysts, our research provides the in-depth business intelligence you need to evaluate, enter and excel in these exciting markets.

View licence options

Suitable for

  • Executives and entrepreneurs
  • Bankers and hedge fund managers
  • Journalists and communications professionals
  • Consultants and advisors of all kinds
  • Academics and students
  • Government and policy-research delegations
  • Diplomats and expatriates

This article also features in Nigeria Health. Read more about this report and view purchase options in our online store.

Nigeria Health

Mojisola Adeyeye

Director General, National Agency for Food and Drug Administration and Control (NAFDAC)

NAFDAC developed its own quality management and auditing systems in cooperation with the World Health Organisation (WHO) that met international benchmarks, and the agency has been working with the WHO to expand our capacity to handle future pandemics.

Health Care in Nigeria

Report Article

Health Care Overview

Although Nigeria has made tangible progress on a number of health and wellness indicators in recent years, the socio-economic and medical impacts of the Covid-19 pandemic took their toll, and the country continues to grapple with challenges.

Report Article

Regulation & Oversight

The FMH is the main government body responsible for providing health services for all Nigerian citizens, with a mandate to implement policies that strengthen the national health system in order to deliver affordable services in partnership with multiple stakeholders.

Report Article

Sector Strategy

In December 2020 Dr Osagie Ehanire, the minister of health, held a press briefing to present the country’s health roadmap for 2021.

Report Article

Key Indicators

Nigeria has recorded notable improvements on several major health and wellness indicators over recent decades, with the World Bank reporting that life expectancy at birth increased by 19% from 46 years in 1998 to 54.7 years in 2019.

Report Article

Private Initiatives

Nigeria finances its health care delivery through a combination of public and private sector initiatives.

Report Article

Covid-19 Vaccination Campaign

In the second year of the pandemic, policy focus in Nigeria shifted to the rollout of Covid-19 vaccines and efforts to prevent new waves of infection.

Health Care Overview
Regulation & Oversight
Sector Strategy
Key Indicators
Private Initiatives
Covid-19 Vaccination Campaign
 

Kunle Oyelana

Managing Director, GSK Nigeria

Nigeria presents substantial investment and growth opportunities for the pharmaceutical industry as a result of strong local demand. As the country with both the largest economy and consumer market on the continent, Nigeria is one of the most important markets for the pharmaceutical industry in the world.

Pharmaceutical Industry

Report Article

Pharmaceutical Industry Overview

Nigeria’s pharmaceutical industry was worth an estimated $1.4bn in 2016. It has the potential to reach $4bn by 2026, representing a compound annual growth rate (CAGR) of 11%, according to a 2017 report by consultancy McKinsey.

Report Article

Local Production

Nigeria has around 115 pharmaceutical firms that produce analgesics, antimalarials, antibiotics, anti-retroviral drugs and vitamins for use in the domestic market, as well as for neighbouring countries.

Report Article

Research & Development

In 2002 Nigeria was one of 10 African countries to endorse a target of allocating 1% of GDP to research and development (R&D); however, the country has fallen short of this goal in the intervening years, with the government pledging to spend 0.5% of GDP on R&D in 2021.

Report Article

Combatting Counterfeits

Counterfeit medicine is a significant issue in the region, with the World Health Organisation (WHO) estimating that Africa accounted for as much of 42% of the world’s fake drugs.

Pharmaceutical Industry Overview
Local Production
Research & Development
Combatting Counterfeits
 

Case Study

Bayer is an internationally operating German life science company with over 150 years of experience in health care and agriculture. In 2015 Bayer expanded its presence in West and Central Africa. Bayer Nigeria aims to improve the quality of life for the country’s growing population by preventing, alleviating and treating diseases, as well as by providing a reliable supply of high-quality food, feed and plant-based raw materials.

With more than 115 registered pharmaceutical manufacturers providing a variety of products to health care professionals, the pharmaceutical industry in Nigeria holds significant growth potential and could be valued at $4bn by 2030, which will underpin broader economic growth. However, the country remains highly dependent on imports to supply its pharmaceutical market.

As governments and businesses continue to take note of this high-potential industry, they also face significant challenges, which include facilitating access to pharmacies in remote areas, strict monitoring and control of distributors of patented drugs, and improving the performance of the logistics chain on a national scale.

The ongoing efforts of the authorities and the industry’s biggest players are mainly focused on facilitating access to quality pharmaceuticals for Nigerians. This is expected to stimulate the growth of the sector, and positively impact the overall health and well-being of the country’s population.

Opportunities & Developments

Report Article

Investment Potential

Against the backdrop of limited public spending and a growing burden of care for an expanding population, there are substantial opportunities for private investment in Nigeria’s health sector.

Report Article

Government Incentives

While the underlying fundamentals of the health care sector and Nigeria’s demographics already make a strong case for investment, government incentives are helping to increase the market’s attractiveness further.

Report Article

Devices & Equipment

According to Fitch Solutions, the Nigerian medical device market is projected to grow at a compound annual growth rate (CAGR) of 15% between 2018 and 2023 to reach N82.7bn.

Report Article

Medical Technology

Technology is transforming health provision in emerging markets — not only in terms of extending care to underserved areas, but also by allowing hospitals to digitise patients records to provide diagnosis and care remotely.

Investment Potential
Government Incentives
Devices & Equipment
Medical Technology